Treatment with ipatasertib plus paclitaxel in the first-line setting demonstrated a trend toward improved overall survival (OS) compared with paclitaxel alone in women with inoperable locally advanced/metastatic triple-negative breast cancer (TNBC), according to final results of the phase II LOTUS trial.
Adding veliparib to a carboplatin-paclitaxel combination improved progression-free survival (PFS) in patients with BRCA1/2 hormone receptor-positive (HR+) or triple-negative breast cancer (TNBC), subgroup analysis of the phase III BROCADE3* trial showed.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.